[go: up one dir, main page]

DE60309598D1 - Als histamin-h3-antagonisten geeignete indolderivate - Google Patents

Als histamin-h3-antagonisten geeignete indolderivate

Info

Publication number
DE60309598D1
DE60309598D1 DE60309598T DE60309598T DE60309598D1 DE 60309598 D1 DE60309598 D1 DE 60309598D1 DE 60309598 T DE60309598 T DE 60309598T DE 60309598 T DE60309598 T DE 60309598T DE 60309598 D1 DE60309598 D1 DE 60309598D1
Authority
DE
Germany
Prior art keywords
indicatives
histamine
antagonists
indicatives suitable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60309598T
Other languages
English (en)
Other versions
DE60309598T2 (de
Inventor
G Aslanian
Y Berlin
Pietro Mangiaracina
Cormick D Mc
W Mutahi
B Rosenblum
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of DE60309598D1 publication Critical patent/DE60309598D1/de
Application granted granted Critical
Publication of DE60309598T2 publication Critical patent/DE60309598T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Anesthesiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE60309598T 2002-06-24 2003-06-20 Als histamin-h3-antagonisten geeignete indolderivate Expired - Lifetime DE60309598T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39098702P 2002-06-24 2002-06-24
US390987P 2002-06-24
PCT/US2003/019619 WO2004000831A1 (en) 2002-06-24 2003-06-20 Indole derivatives useful as histamine h3 antagonists

Publications (2)

Publication Number Publication Date
DE60309598D1 true DE60309598D1 (de) 2006-12-21
DE60309598T2 DE60309598T2 (de) 2007-09-13

Family

ID=30000654

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60309598T Expired - Lifetime DE60309598T2 (de) 2002-06-24 2003-06-20 Als histamin-h3-antagonisten geeignete indolderivate

Country Status (22)

Country Link
US (1) US6951871B2 (de)
EP (2) EP1777223A1 (de)
JP (1) JP4326468B2 (de)
KR (1) KR20050009757A (de)
CN (1) CN100497334C (de)
AR (1) AR039718A1 (de)
AT (1) ATE344798T1 (de)
AU (1) AU2003243709B2 (de)
CA (1) CA2489337C (de)
CY (1) CY1105986T1 (de)
DE (1) DE60309598T2 (de)
DK (1) DK1539742T3 (de)
ES (1) ES2271644T3 (de)
HK (1) HK1072259A1 (de)
IL (1) IL165863A0 (de)
MX (1) MXPA05000193A (de)
MY (1) MY135686A (de)
NZ (1) NZ537200A (de)
PT (1) PT1539742E (de)
TW (1) TW200400031A (de)
WO (1) WO2004000831A1 (de)
ZA (1) ZA200410213B (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020507A1 (es) * 2000-10-17 2002-06-25 Schering Corp Compuestos no-imidazoles como antagonistas del receptor histamina h3
ATE384698T1 (de) * 2002-06-28 2008-02-15 Euro Celtique Sa Therapeutische piperazin-derivate für die behandlung von schmerzen
ES2387909T3 (es) 2003-01-14 2012-10-03 Cytokinetics, Inc. Compuestos, composiciones y procedimientos de tratamiento de la insuficiencia cardiaca
MY144470A (en) * 2004-06-17 2011-09-30 Cytokinetics Inc Compounds, compositions and methods
DK1761519T3 (da) 2004-06-21 2008-07-21 Hoffmann La Roche Indolderivater som histaminreceptorantagonister
US7176222B2 (en) 2004-07-27 2007-02-13 Cytokinetics, Inc. Syntheses of ureas
FR2878849B1 (fr) * 2004-12-06 2008-09-12 Aventis Pharma Sa Indoles substitues, compositions les contenant, procede de fabrication et utilisation
KR20070100277A (ko) * 2004-12-06 2007-10-10 아벤티스 파마 소시에떼아노님 치환된 인돌, 그를 함유하는 조성물, 그의 제조 방법 및그의 용도
ATE437856T1 (de) 2005-01-19 2009-08-15 Hoffmann La Roche 5-aminoindol-derivate
CA2609957A1 (en) 2005-06-20 2007-01-04 Schering Corporation Carbon-linked substituted piperidines and derivatives thereof useful as histamine h3 antagonists
JP2008546784A (ja) * 2005-06-20 2008-12-25 シェーリング コーポレイション ヒスタミンｈ３アンタゴニストとして有用なピペリジン誘導体
CA2606004A1 (en) * 2005-08-02 2007-02-08 Neurogen Corporation Dipiperazinyl ketones and related analogues
US7538223B2 (en) 2005-08-04 2009-05-26 Cytokinetics, Inc. Compounds, compositions and methods
WO2007035703A1 (en) 2005-09-20 2007-03-29 Schering Corporation 1- [ [1- [ (2-amin0-6-methyl-4-pyridinyl) methyl] -4-flu0r0-4-piperidinyl,] carbonyl] -4- [2- (2-pyridinyl) -3h-imidaz0 [4 , 5-b] pyridin-3-yl] piperidine useful as histamine h3 antagonist
GB2431927B (en) 2005-11-04 2010-03-17 Amira Pharmaceuticals Inc 5-Lipoxygenase-activating protein (FLAP) inhibitors
US7977359B2 (en) 2005-11-04 2011-07-12 Amira Pharmaceuticals, Inc. 5-lipdxygenase-activating protein (FLAP) inhibitors
WO2007057329A1 (en) 2005-11-18 2007-05-24 F. Hoffmann-La Roche Ag Azaindole-2-carboxamide derivatives
CN101316835A (zh) 2005-11-30 2008-12-03 霍夫曼-拉罗奇有限公司 5-取代的吲哚-2-甲酰胺衍生物
TW200808321A (en) 2005-12-15 2008-02-16 Cytokinetics Inc Certain chemical entities, compositions and methods
US7825120B2 (en) 2005-12-15 2010-11-02 Cytokinetics, Inc. Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas
EP1959962A2 (de) 2005-12-16 2008-08-27 Cytokinetics, Inc. Bestimmte chemische stoffe, zusammensetzungen und verfahren
JP5178526B2 (ja) 2005-12-19 2013-04-10 サイトキネティクス・インコーポレーテッド 化合物、組成物および方法
WO2007075555A2 (en) * 2005-12-21 2007-07-05 Schering Corporation Combination of an h3 antagonist/inverse agonist and an appetite suppressant
CA2634250A1 (en) * 2005-12-21 2007-07-05 Schering Corporation Phenoxypiperidines and analogs thereof useful as histamine h3 antagonists
WO2007075688A2 (en) 2005-12-21 2007-07-05 Schering Corporation Substituted aniline derivatives useful as histamine h3 antagonists
WO2007098418A1 (en) * 2006-02-17 2007-08-30 Memory Pharmaceuticals Corporation Compounds having 5-ht6 receptor affinity
US7514433B2 (en) 2006-08-03 2009-04-07 Hoffmann-La Roche Inc. 1H-indole-6-yl-piperazin-1-yl-methanone derivatives
ATE537166T1 (de) * 2006-10-27 2011-12-15 Boehringer Ingelheim Int Piperidylpropanthiole als ccr3-modulatoren
CA2667548C (en) * 2006-10-27 2015-02-03 Boehringer Ingelheim International Gmbh Substituted piperidyl-propane-thiols
CA2695456A1 (en) * 2007-08-15 2009-02-19 Robert Dunn 3' substituted compounds having 5-ht6 receptor affinity
CA2739668C (en) * 2008-01-04 2016-10-11 Schabar Research Associates Llc The use of analgesic potentiating compounds to potentiate the analgesic properties of an analgesic compound
EA019819B1 (ru) 2008-05-23 2014-06-30 ПАНМИРА ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Кристаллическая полиморфная форма с ингибитора белка, активирующего 5-липоксигеназу, фармацевтическая композиция на ее основе и применение в лечении
US20100016297A1 (en) * 2008-06-24 2010-01-21 Memory Pharmaceuticals Corporation Alkyl-substituted 3' compounds having 5-ht6 receptor affinity
WO2009158375A1 (en) * 2008-06-25 2009-12-30 Abbott Laboratories Aza-cylic indole- 2 -carboxamides and methods of use thereof
AR072297A1 (es) 2008-06-27 2010-08-18 Novartis Ag Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona.
US20110130385A1 (en) * 2008-07-23 2011-06-02 De Lera Ruiz Manuel Bicyclic Heterocylic Derivatives and Methods of Use
US20100029629A1 (en) * 2008-07-25 2010-02-04 Memory Pharmaceuticals Corporation Acyclic compounds having 5-ht6 receptor affinity
US20100056531A1 (en) * 2008-08-22 2010-03-04 Memory Pharmaceuticals Corporation Alkyl-substituted 3' compounds having 5-ht6 receptor affinity
US9024041B2 (en) 2010-04-08 2015-05-05 Respivert Ltd. P38 MAP kinase inhibitors
CN103096893B (zh) 2010-06-04 2016-05-04 阿尔巴尼分子研究公司 甘氨酸转运体-1抑制剂、其制备方法及其用途
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
TWI748194B (zh) 2018-06-28 2021-12-01 德商菲尼克斯 Ｆｘｒ有限責任公司 含有雙環核心部分之新穎lxr調節劑
EP3797769A1 (de) 2019-09-25 2021-03-31 Fontès, M. Michel Zusammensetzung für den therapeutischen einsatz
AU2021310264A1 (en) 2020-07-15 2023-02-09 Schabar Research Associates Llc Unit oral dose compositions composed of ibuprofen and famotidine for the treatment of acute pain and the reduction of the severity and/or risk of heartburn
US11324727B2 (en) 2020-07-15 2022-05-10 Schabar Research Associates, Llc Unit oral dose compositions composed of naproxen sodium and famotidine for the treatment of acute pain and the reduction of the severity of heartburn and/or the risk of heartburn

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0730037B2 (ja) 1987-03-13 1995-04-05 第一製薬株式会社 ピリミジニルプロピオン酸誘導体
DK181190D0 (da) 1990-07-30 1990-07-30 Lundbeck & Co As H 3-aryl-indol- eller 3-aryl-indazolderivater
US5217986A (en) * 1992-03-26 1993-06-08 Harbor Branch Oceanographic Institution, Inc. Anti-allergy agent
US5352707A (en) * 1992-03-26 1994-10-04 Harbor Branch Oceanographic Institution, Inc. Method for treating airway congestion
US5846982A (en) * 1996-06-14 1998-12-08 Eli Lilly And Company Inhibition of serotonin reuptake
ATE314071T1 (de) 1996-08-16 2006-01-15 Schering Corp Behandlung von allergischen reaktionen im oberen respirationstrakt mit einer kombination von histamin-rezeptor-antagonisten
WO1998023610A1 (en) * 1996-11-25 1998-06-04 The Procter & Gamble Company 2-imidazolinylaminoindole compounds useful as alpha-2 adrenoceptor agonists
US5869479A (en) * 1997-08-14 1999-02-09 Schering Corporation Treatment of upper airway allergic responses
WO2001046181A1 (en) 1999-12-20 2001-06-28 Eli Lilly And Company Indole derivatives for the treatment of depression and anxiety
PE20020507A1 (es) * 2000-10-17 2002-06-25 Schering Corp Compuestos no-imidazoles como antagonistas del receptor histamina h3
ES2172436B1 (es) * 2000-10-31 2004-01-16 Almirall Prodesfarma Sa Derivados de indolilpiperidina como agentes antihistaminicos y antialergicos.
JP2004529117A (ja) * 2001-02-08 2004-09-24 シェーリング　コーポレイション 認知欠陥障害の処置における二重のｈ３／ｍ２アンタゴニストの使用
AU2002244271A1 (en) * 2001-03-13 2002-09-24 Pharmacopeia, Inc. Non-imidazole compounds as histamine h3 antagonists

Also Published As

Publication number Publication date
NZ537200A (en) 2007-09-28
CY1105986T1 (el) 2011-04-06
JP2005531615A (ja) 2005-10-20
DK1539742T3 (da) 2006-12-27
WO2004000831A1 (en) 2003-12-31
ATE344798T1 (de) 2006-11-15
CN1662524A (zh) 2005-08-31
PT1539742E (pt) 2007-01-31
TW200400031A (en) 2004-01-01
AU2003243709A1 (en) 2004-01-06
AU2003243709B2 (en) 2007-01-18
CA2489337A1 (en) 2003-12-31
HK1072259A1 (en) 2005-08-19
CA2489337C (en) 2010-05-25
EP1539742B1 (de) 2006-11-08
IL165863A0 (en) 2006-01-15
JP4326468B2 (ja) 2009-09-09
MY135686A (en) 2008-06-30
KR20050009757A (ko) 2005-01-25
EP1777223A1 (de) 2007-04-25
EP1539742A1 (de) 2005-06-15
CN100497334C (zh) 2009-06-10
ZA200410213B (en) 2005-10-20
MXPA05000193A (es) 2005-04-08
DE60309598T2 (de) 2007-09-13
US20040019099A1 (en) 2004-01-29
AR039718A1 (es) 2005-03-09
US6951871B2 (en) 2005-10-04
ES2271644T3 (es) 2007-04-16

Similar Documents

Publication Publication Date Title
DE60309598D1 (de) Als histamin-h3-antagonisten geeignete indolderivate
ATE384053T1 (de) Triazolderivate als tachykininrezeptor- antagonisten
NO20052923D0 (no) Fusjonerte bicykliske nitrogeninneholdende heteroringer
EP1546115A4 (de) Substituierte pyrimidine
DK1638969T3 (da) CGRP-receptorantagonister
ATE452891T1 (de) Pyrimidopyrimidone als kinaseinhibitoren
DE60315389D1 (de) Resttonersammelbehälter
ATE461191T1 (de) N-substituierte 2-oxodihydropyridinderivate als npy antagonisten
DE60317391D1 (de) Verbinder
DK1597007T3 (da) Borepatron
DE50300841D1 (de) Bohrfutter
DE60208885D1 (de) Verbinder
DE502004005307D1 (de) Schnellspannfutter
DE60315937D1 (de) Verbinder
DE602004005238D1 (de) Hydroxyalkylsubstituierte pyrido-7-pyrimidin-7-one
DE60316411D1 (de) Thiazolderivate als npy-rezeptorantagonisten
DE60223352D1 (de) Verbinder
DE50302584D1 (de) Stereomikroskop
SE0301827L (sv) Verktyg
DE50302514D1 (de) Stereomikroskop
DE10301279B8 (de) Verbinder
DE50311910D1 (de) Bohrfutter
DE60218623D1 (de) Verbinder
DE60312105D1 (de) Verbinder
DE502004003322D1 (de) Schnellspannfutter

Legal Events

Date Code Title Description
8364 No opposition during term of opposition